Next-Generation Targeted Oncology Drug Market Size
The global next-generation targeted oncology drug market size was valued at USD 15.26 billion in 2025 and is expected to reach USD 40.85 billion by 2033, at a CAGR of 13.10% during the forecast period
The market growth is largely fueled by the rising global burden of cancer, increasing demand for precision and personalized therapies, and rapid advancements in biotechnology such as CAR-T, mRNA platforms, and bispecific antibodies, driving innovation in targeted treatment approaches
𝐕𝐢𝐬𝐢𝐭 𝐮𝐬 𝐧𝐨𝐰 -
Furthermore, growing investment in next-generation oncologic R&D, expanding clinical trial activity, and increasing adoption of effective targeted therapies with improved clinical outcomes and fewer side effects are establishing next-generation oncology drugs as the preferred choice in modern cancer care. These converging factors are accelerating market uptake, thereby significantly boosting the industry’s growth